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Abstract
Background: DB289, [2,5-bis(4-amidinophenyl)furan bis-O-methylamidoxime], is a broad
spectrum anti-parasitic compound which has been shown to be effective against malaria in recent
clinical trials. DB75, [2,5-bis(4-amidinophenyl)furan], is the active metabolite of this drug. The
objective of this study was to determine the mechanism of action of DB75 in Plasmodium falciparum.
Methods: Live parasites were observed by confocal microscopy after treatment with organelle
specific dyes and DB75, an inherently fluorescent compound. Parasites were exposed to DB75 and
assessed for growth and morphological changes over time using blood smears and light microscopy.
Also, to determine if DB75 affects gene transcription, real time PCR was used to monitor transcript
levels over time for six developmentally expressed genes, including trophozoite antigen R45-like
(PFD1175w), lactate dehydrogenase (PF13_0141), DNA primase (PFI0530c), isocitrate dehydrogenase
(PF13_0242), merozoite surface protein-1 (PFI1475w), and merozoite surface protein-7 (PF13_0197).
Results: The results show that DB75 localizes in the parasite nucleus but not in other organelles.
Once rings are exposed, parasites mature to the trophozoite stage and stall. No stage-dependent
or gene-specific inhibition of transcription was seen. However, DB75 delayed peak transcription of
trophozoite-stage genes.
Conclusion: Taken together, DB75 appears to concentrate in the nucleus and delay parasite
maturation.
Background
Resistance to classical anti-malarials exists throughout the
developing world [1]. Most of the current anti-malarials
belong to a few classes of compounds for which cross-
resistance exists. New anti-malarials with unique targets
are needed to overcome cross-resistance.
Pentamidine, [1,5-di(4-amidinophenoxy)pentane], a
dicationic diamidine, has been used for clinical treatment
of protozoa infections such as leishmaniasis and Human
African Trypanosomiasis (HAT) [2]. It also has activity
against Plasmodium falciparum, but pentamidine is not
orally bioavailable and has considerable side effects,
including renal toxicity and cardiotoxicity [3-5]. There-
fore, it has been passed over as a potential malaria thera-
peutic in favour of drugs with oral bioavailability and
fewer side effects [5]. New pentamidine structural ana-
logues have been synthesized and represent a class of
broad-spectrum antimicrobials lacking the side effects
associated with pentamidine [6,7]. The aromatic diami-
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therapeutic use with HAT, malaria, Pneumocystis jiroveci
pneumonia (PCP) and leishmaniasis [2,6].
The dicationic diamidine, DB75, [2,5-bis(4-amidinophe-
nyl)furan], is a fluorescent structural analogue of penta-
midine with antimicrobial activity, but with little oral
bioavailability [6,8,9]. Pafuramidine, also known as
DB289, [2,5-bis(4-amidinophenyl)furan bis-O-methyla-
midoxime], is an orally active pro-drug of DB75 [7,10,11].
In a clinical trial of Thai patients with falciparum malaria,
DB289 monotherapy (100 mg, twice daily for 5 days)
exhibited a 96% (22 of 23) cure rate [10].
The target and mechanism of action of diamidines against
malaria are currently unknown, but several possible
mechanisms have been proposed. First, Stead et al showed
that pentamidine is found in the food vacuole of P. falci-
parum where it binds toxic haem and inhibits formation
of non-toxic haemozoin [12]. Second, DNA-containing
organelles are also potential targets. In Trypanosoma brucei
gambiense, DB75 localizes in DNA-containing organelles,
such as the nucleus and kinetoplast [13,14]. Further,
nucleic acid-binding is believed to inhibit topoisomerase
II, a DNA replication enzyme, in Giardia lamblia [9,15].
Also, DB75 inhibits cellular respiration in the mitochon-
dria of Sacchharomyces cerevisiae and trypanosomes [13]
Finally, DB75 localizes in acidocalcisomes of trypano-
somes where it may interrupt calcium homeostasis [14].
Plasmodium also possess acidocalcisomes that regulate
calcium homeostasis in a manner similar to other proto-
zoan [16].
The objective of this investigation was to elucidate the
mechanism of action for DB75 in P. falciparum.
Methods
Parasite cultivation
3D7 P. falciparum strain was maintained with 2% (v/v) O+
human erythrocytes (Research Blood Components,
Brighton, MA) in 1640 RPMI supplemented with 25 mM
HEPES (Sigma), 2 mM L-glutamine (Gibco), 0.45% (w/v)
glucose (Sigma), 0.05 ng/ml gentamycin (Sigma), 0.1 mM
hypoxanthine and 10% (v/v) O+ human serum (Research
Blood Components). Cultures were maintained by the
Trager and Jensen method in candle jars at 37°C [17].
[3H]-Hypoxanthine incorporation assay
[3H]-hypoxanthine incorporation into parasite DNA was
measured in the presence and absence of DB75 to assess
parasite drug susceptibility in vitro [18]. Parasite cultures
were diluted to 0.7% parasitaemia in complete medium
(without supplemental hypoxanthine). Parasites were
sub-cultured in 96-well flat bottom microtitre plates with
serial dilutions of DB75 at final concentrations ranging
from 1 μM to 3.9 nM, in duplicate or triplicate.
To measure growth in 42 hours, the 96-well plates were
incubated for 24 hours prior to addition of 0.5 μCi of
[3H]-hypoxanthine diluted in hypoxanthine-free com-
plete media (25 μL/well). The cells were incubated for an
additional 18 hours and harvested using an Inotech cell
harvester and glass fiber filter paper (Inotech Systems
International, INC.). Radioactivity of samples was deter-
mined in a liquid scintillation counter (Beckman-Coul-
ter) [18]. Background absorption of [3H]-hypoxanthine
by erythrocytes was controlled for using uninfected eryth-
rocytes, and maximum parasite growth was controlled for
using non-treated parasites.
To measure growth in 36 hours, [3H]-hypoxanthine was
added for the final 18-hour incubation. To measure
growth in 96 hours, 25 μL of medium was removed at 48
hours and replaced with fresh medium containing [3H]-
hypoxanthine and DB75 for the final 48-hour incubation.
DB75 concentration required to inhibit 50% of parasite
growth (IC50) was calculated using sigmoidal dose
response nonlinear regression equation in GraphPad
Prism® (version 4.0). The mean IC50 ± SEM for 42-hour
growth was calculated from 12 experiments. For 36- and
96-hour experiments, the IC50 ± SEM was calculated from
two experiments.
Confocal microscopy
Asynchronous parasite-infected red blood cells were
stained with fluorescent dyes for subcellular localization
studies. Cells were treated with MitoTracker Red CMXRos
(Invitrogen), which is a mitochondrion-specific dye or
LysoTracker® Red DND-99 (Invitrogen), an acidophilic
dye that localizes to the parasite food vacuole [19,20].
Cells were also treated with Draq5™ (Axxora, LLC), a
nuclear DNA dye in addition to the inherently fluorescent
compound, DB75 [21].
To determine if DB75 co-localizes with MitoTracker Red,
red blood cells infected with viable asynchronous para-
sites suspended in medium were incubated with 25 nM
MitoTracker Red for 30 minutes at 37°C in a candle jar.
The cells were centrifuged and resuspended in pre-
warmed complete medium to remove the mitochondrial
dye from the extracellular medium. 1 μM DB75 was
added and cells were transported to the Michael Hooker
Microscopy facility (15 minutes) where 1 μM of the DNA
dye was added immediately prior to slide preparation. To
determine if DB75 co-localizes with LysoTracker Red,
infected red blood cells were prepared as described above
except cells were incubated with 50 nM of LysoTracker.Page 2 of 9
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was added to infected red blood cells suspended in
medium prior to transport to the microscopy location. 1
μM of the nuclear dye was added immediately prior to
slide preparation.
To determine subcellular localization with short-term
drug exposure, infected red blood cells (> 5% parasitae-
mia) were incubated with 1 μM DB75 for less than four
hours prior to microscopy. For long-term drug exposure,
infected red blood cells (3% parasitaemia) were exposed
to 100 nM DB75 for 24, 48 or 72 hours. Dyes for co-local-
ization with DB75 were added after the long exposure
periods to determine the subcellular localization of the
drug. To determine if DB75 remains in the parasite after
extracellular drug pressure is relieved, parasites were
exposed to DB75 for 24 hours and then washed by centrif-
ugation and resuspended in drug-free pre-warmed
medium. The parasites were incubated for an additional
48 hours prior to microscopy.
For confocal microscopy, live cells were examined under a
cover slip using a Leica 2SP Laser Scanning Confocal
Microscope. The 561 nm Solid State laser was used to cap-
ture MitoTracker (absorbance/emission: 579 nm/599
nm) or LysoTracker (absorbance/emission: 577 nm/590
nm); a UV laser (364 nm) for DB75 (absorbance/emis-
sion 365 nm/465 nm) and Red HeNe laser to capture
Draq5™ (absorbance/emission: 647 nm/670 nm). A spec-
tral scan was used to identify changes in the emission
spectrum of DB75. Adobe Photoshop (v.7.0) was used to
create overlaid confocal images and to adjust dye contrast
for publication.
Parasite maturation assay
To determine the effect of DB75 on parasite development,
morphology was assessed after prolonged drug exposure.
Parasite cultures were synchronized every 48 hours for
three consecutive life cycles prior to a 24–48 hour recov-
ery period [22]. Synchronized ring or trophozoite para-
sites (0.3% parasitaemia) were exposed to DB75 for 96
hours. Medium for each sample was exchanged at 48
hours with fresh medium and DB75. Non-treated syn-
chronized cultures were used as a control. Thin blood
smears were prepared and stained with Giemsa at 0, 12,
24, 36, 48, 60, 72, 84 and 96 hours post-exposure and
examined with light microscopy to assess parasitaemia
and parasite morphology. Parasitaemia was determined
by calculating the number of parasite-infected red blood
cells per at least 1000 total red blood cells. Parasite mor-
phology was examined and the number of rings, tropho-
zoites and schizonts was assessed for at least 100 parasites.
Parasites with the "ring" structure and a single nucleus
were classified as ring stage parasites. Parasites containing
a single nucleus and haemozoin were classified as tropho-
zoites. Multi-nucleated parasites with ample haemozoin
were classified as schizonts. Results are representative of
three separate experiments.
Gene expression
Red blood cells infected with sorbitol-synchronized rings
were exposed to 100 nM or 500 nM DB75 for 48 hours.
Non-treated cells were used as a control. At 0, 6, 12, 18,
24, 36 and 48 hours, RNA and DNA were immediately
extracted from the harvested cells using the Allprep kit
(Qiagen). Also, blood smears were prepared for assess-
ment of morphology and parasitaemia at each time point.
RNA concentrations were measured using a NanoDrop
1000 (NanoDrop Technologies). 50 ng of total RNA was
reverse transcribed using SuperScript® II (Invitrogen) with
2.2 μM Pd(N)6 Random Hexamer (GE Healthcare) and
2.2 μM Oligo(dT)20 primers (Invitrogen) according to
the manufacturer's protocols. All cDNA samples were
diluted by a factor of 50 in sterile, RNase free water, and 5
μL was subsequently used for Real Time PCR to measure
expression in six developmentally-regulated genes. Prim-
ers were designed using Primer Express v3.0 (Applied Bio-
systems) (Additional file 1).
Real Time PCR was performed using an Applied Biosys-
tems 7300 Real-Time PCR System (Applied Biosystems)
with Power SYBR® Green PCR Master Mix (Applied Biosys-
tems). cDNA was amplified with 40 cycles of: 95° for 15",
55° for 30", 72° for 30". A dissociation curve for ampli-
con melting temperature analysis was performed immedi-
ately following amplification to monitor nonspecific
amplification (contamination or primer dimer amplifica-
tion).
The expression of each gene relative to a constitutively
expressed gene was analysed for each sample [23]. Expres-
sion of six developmentally expressed genes were
assessed: trophozoite antigen R45-like (ring stage), lactate
dehydrogenase (late ring stage), DNA primase (trophozoite
stage), isocitrate dehydrogenase (trophozoite stage), mero-
zoite surface protein-1 (schizont stage), merozoite surface pro-
tein-7 (schizont stage) (Additional file 1) [24]. In
replicates on the same reaction plate, amplification of
cDNA for a developmentally-regulated gene was com-
pared to that of the constitutively expressed, 18s rRNA.
The amplification efficiency for each primer pair was cal-
culated based on the slope of the line representing cycle
threshold (CT) values versus 3D7 genomic DNA concen-
trations from five separate experiments as previously
described [23]. To determine the relative fold change in
expression over time for each developmentally-regulated
gene, the following equation was used [23]:
Fold Change in Gene Expression
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the developmentally-regulated gene of interest, t is the
time of drug exposure, t = 0 is the start of the experiment
and ref is the 18s rRNA reference gene [23]. This method
accounts for variations in cDNA concentrations (loading
control) and differences in primer efficiency. Data were
graphed using GraphPad Prism® (v.4.03). Results are rep-
resentative of two separate experiments.
Results and discussion
DB75 inhibits P. falciparum growth
To determine the anti-malarial activity of DB75 in vitro,
tritiated hypoxanthine incorporation was measured.
DB75 had an IC50 of 124 ± 10 nM (mean ± SD) with
asynchronous parasites exposed for 42 hours (Figure 1).
When synchronized ring and trophozoite cultures were
exposed to DB75 for 36 hours, the IC50 for rings was 143
± 8 nM compared to 711 ± 32 nM for exposed tropho-
zoites (mean ± SEM), suggesting that rings are particularly
sensitive to DB75 (Figure 1). The IC50 was reduced to 1.5
± 0.2 nM for synchronized rings exposed for 96 hours,
suggesting longer incubations increase DB75 inhibitory
activity (Figure 1).
Fluorescent localization of DB75 in P. falciparum
The intrinsic fluorescent properties of DB75 were used to
determine its potential subcellular localization in P. falci-
parum using confocal microscopy. To identify possible
sub-cellular targets, infected red blood cells were incu-
bated with DB75 and different organelle-specific dyes [19-
21]. In parasites exposed to 100 nM or up to 1 μM drug
for less than four hours, DB75 co-localized only with
Draq5™, the nuclear DNA stain. Nuclear co-localization
was evident in all parasite life stages except the ring stage
with short-term exposure (Figure 2), suggesting that the
drug initially localizes in the nucleus and may require a
stage-specific uptake mechanism that prevents accumula-
tion in ring stage parasites. DB75 had a distinct and sepa-
rate staining pattern from the red-fluorescing LysoTracker
or MitoTracker, suggesting that DB75 does not co-localize
with these dyes in the food vacuole or mitochondrion
immediately after drug exposure. 3-D compilations of z-
series images confirmed DB75 co-localized only with
Draq5™ and not LysoTracker or MitoTracker (Additional
files 2 and 3).
To determine if DB75 localizes to other subcellular com-
partments over time, asynchronous parasites were
exposed to a therapeutic concentration (100 nM) of DB75
for 24, 48 or 72 hours. Despite the longer incubation,
DB75 co-localized only with Draq5™ following 24, 48 or
72 hours, suggesting the drug targets the nucleus of the
parasites with extended exposures (Figure 3). DB75 co-
localization with Draq5™ was noted in all life stages after
24 hours of exposure, including rings. Although DB75
was not evident in ring-stage parasites with short-term
drug exposure, the presence of DB75 in rings after
extended drug exposure suggests DB75 may not be trans-
ported into the cell during the early part of the life stage.
However, with extended exposure DB75 localization in
the nucleus of schizonts likely persists as the host cell rup-
tures and merozoites invade uninfected erythrocytes and
mature to the ring stage.
DB75 inhibition of P. falciparumFigure 1
DB75 inhibition of P. falciparum. The percent inhibition 
of parasite growth was measured with tritiated hypoxanthine 
for asynchronous parasites exposed to drug for 42 hours 
(grey line, open circle); synchronized ring-stage parasites 
exposed to drug for 36 hours (black line, closed square); syn-
chronized rings-stage parasites exposed to drug for 96 hours 
(black line, open square); and synchronized trophozoite-
stage parasites exposed to drug for 36 hours (black line, 
closed triangle).
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DB75 subcellular distribution in different P. falciparum life stages upon imme iate cell entry (< 4 hours)Figure 2
DB75 subcellular distribution in different P. falci-
parum life stages upon immediate cell entry (< 4 
hours). (A) 1 μM DB75 (blue) and LysoTracker Red show 
no co-localization of the food vacuole of a trophozoite. (B) In 
a schizont, 1 μM DB75 co-localizes with green nuclear 
Draq5™ stain but not MitoTracker Red. (C) 1 μM DB75 flu-
orescence is not present in ring stage parasites. All images 
are representative.Page 4 of 9
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red blood cells to 100 nM DB75, the drug's emission spec-
trum undergoes a shift from 465 nm (blue) to 558 nm
(yellow), although still localized to the nucleus (Figure 4).
This spectral shift may be the result of high concentrations
of the compound, as is seen with the DNA-binding dye,
Hoechst [25]. A similar shift from blue to yellow fluores-
cence is also observed by epifluorescence in trypanosomes
exposed to 7.5 μM DB75 [14].
To determine if and where DB75 persists in the cell after
drug pressure was removed, live cells were assessed with
co-localization dyes 48 hours after drug was removed.
When P. falciparum cells were washed after 24 hours of
continuous exposure to 100 nM DB75, the blue DB75 flu-
orescence was still observed in the nucleus of cells at 48
and 72 hours post-exposure by colocalization with
Draq5™. However, only the blue fluorescence (465 nm
emission) was detected (Figure 3). This suggests that the
drug remains in the nucleus, perhaps bound to DNA, but
does not accumulate to high levels that may result in the
fluorescence shift from blue to yellow.
All DB75-treated parasites appeared to be unhealthy or
dead following 72 hours of continuous exposure to 100
nM DB75 (Figure 4). Many parasites were outside of the
host red blood cells, and all exhibited condensed nuclei.
Effects of DB75 on parasite maturation
The development of different parasites stages over 96
hours, under normal conditions, can be seen in Figure 5a.
Untreated cultures consisting of synchronized rings pro-
gressed through two lifecycles, to cultures which were pre-
dominantly trophozoites (peaking at 24 hours) schizonts
(36 hours), then rings (60 hours), trophozoites (72
hours) and schizonts (≥ 96 hours) again. However, when
synchronized rings were exposed to DB75, parasites
matured into the first wave of trophozoites and schizonts
normally, but not into the second wave of rings or subse-
quent stages (Figure 5b).
The situation was different for experiments initiated with
parasites synchronized at the trophozoite stage. Untreated
cultures of trophozoites also progressed through two life
cycles as expected (Figure 5c). When cultures were
exposed to DB75, there was no effect on the timing or
magnitude of the first ring population. However, there
was a significant delay in the appearance of the second
DB75 subcellular distribution following long-term drug expo-sureFigure 3
DB75 subcellular distribution following long-term 
drug exposure. (A) Trophozoite-infected erythrocytes 
after exposure to 100 nM DB75 for 24 hours. Note co-local-
ization of DB75 and nuclear DNA stain, Draq5™. (B) Drug 
was removed by washing at 24 hours and infected erythro-
cytes incubated for an additional 48 hours in drug-free 
medium. Note persistent co-localization of DB75 and 
Draq5™ in nucleus of pycnotic infected erythrocyte.
DB75 distribution in an erythrocyte infected with multiple parasites following 72 hours of exposureFigure 4
DB75 distribution in an erythrocyte infected with 
multiple parasites following 72 hours of exposure. 
DB75 emits at both 465 nm (b) and 558 nm (c) with 
extended exposure. The fluorescence emitted at these wave-
lengths overlay with Draq5™ (f and g). Shown are red cells 
infected with crisis forms.
Parasite morphology with 96 hour continuous DB75 expo-su eFigure 5
Parasite morphology with 96 hour continuous DB75 
exposure. (a and b) Synchronized rings or (c and d) tropho-
zoites (a and c) without treatment or (b and d) with expo-
sure to 100 nM DB75 (b and d) for 96 hours. The number of 
ring (yellow), trophozoite (green) and schizonts (purple) are 
shown per 1000 red blood cell over time. Note: the x-axis of 
(b) is on a different scale.
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instead of 48 hours as in untreated parasites. Furthermore,
few schizonts or rings appeared after this peak in the
treated cultures.
DB75 effect on gene transcription
The effect of drug on transcription was measured for six
developmentally regulated genes (Additional file 1) [24].
With synchronized ring-stage parasites, the transcription
profiles were assessed for alterations in genes expressed
during specific life stages relative to a constitutively-
expressed gene.
For genes normally expressed during the early life stages,
trophozoite antigen R45-like and lactate dehydrogenase, peak
expression occurred in the first 12 hours following inva-
sion for untreated rings (Figure 6a). A similar pattern was
observed for cells exposed to 100 nM or 500 nM DB75
(peak expression, 12 hours). The fold change in expres-
sion (peak intensity) relative to 18s rRNA for these early
transcribed genes varied little with DB75 exposure. The
peak intensity in non-treated cells was 2.0 for lactate dehy-
drogenase and 2.2 or 1.7 with addition of 100 nM or 500
nM DB75, respectively (Figure 6b). Similarly, peak inten-
sity for trophozoite antigen R45-like was 1.0 for both non-
treated and treated cells. The DB75 treatment had little or
no effect on the timing or intensity of expression of these
early genes.
The effects of DB75 were also measured for two tropho-
zoite-specific transcripts: isocitrate dehydrogenase or DNA
primase. Peak expression for these genes in untreated rings
occurred later than expected at 36 and 48 hours, respec-
tively (Figure 6a). Unlike the ring-stage genes, peak
expression for the trophozoite-specific transcripts was
altered with addition of drug. With 100 nM DB75, the
expression of isocitrate dehydrogenase occurred in exposed
rings at 30 hours post-invasion, which is six hours earlier
than non-treated cells (Figure 6a). The highest concentra-
tion of DB75 had the opposite effect. Peak expression was
delayed six hours to 42 hours post-invasion. 500 nM
DB75 also delayed expression of DNA primase by 12 hours
relative to non-treated cells (60 hours). The delays
observed with the highest concentration of DB75 were
consistent with the delay in maturation.
The intensity of peak expression for both isocitrate dehydro-
genase and DNA primase with 500 nM DB75 was increased
(Figure 6b). This is especially evident for DNA primase
where there was a 61-fold increase in expression in non-
treated cells but 192-fold increase with addition of 500
nM DB75. The lower concentration of DB75 did not have
a pronounced effect on peak intensity for either isocitrate
dehydrogenase or DNA primase (57-fold) compared to non-
treated cells (Figure 6b). Thus, the expression of the tro-
phozoite-stage genes are both delayed and increased by
500 nM drug.
The effect of drug was also measured on genes expressed
during the schizont stage, merozoite surface protein-1 and
Effect of DB75 on peak expression time and intensityFigure 6
Effect of DB75 on peak expression time and intensity. 
Expression profiles for six developmentally expressed genes 
were compared in synchronized rings with exposure to 100 
nM (grey) or 500 nM (black) DB75 or left untreated (white). 
(a) Time of invasion was approximated based on assessment 
of morphology, and peak expression post-invasion was esti-
mated for all genes. (b) Expression intensity at time of peak 
expression was measured as the fold change in expression 
relative to the constitutively expressed 18s rRNA for 
exposed rings. Genes evaluated include: trophozoite antigen 
r45-like (Troph Ag); lactate dehydrogenase (ldh), isocitrate dehy-
drogenase (Iso);DNA primase (DNAp), Merozoite surface pro-
tein-1 (MSP-1); Merozoite surface protein-7(MSP-7).
Tro
ph
 
Ag LD
H Iso
DN
Ap
MS
P-7
MS
P-1
0
6
12
18
24
30
36
42
48
54
60
a.
Gene
Ti
m
e 
 
(h
r)
Tro
ph
 
Ag LD
H Iso
DN
Ap
MS
P-7
MS
P-1
0.1
1
10
100
1000
b.
Fo
ld
  C
ha
n
ge
 
(lo
g 1
0)Page 6 of 9
(page number not for citation purposes)
Malaria Journal 2009, 8:104 http://www.malariajournal.com/content/8/1/104merozoite surface protein-7. For non-treated ring stage cells,
peak expression occurred at 48 hours post invasion, when
parasites were at the schizont stage. There was no change
in merozoite surface protein-7 peak expression time with
100 nM DB75 (48 hours) (Figure 6a). However, the same
concentration of DB75 delayed peak expression of mero-
zoite surface protein-1. Additionally, 500 nM DB75 delayed
the expression of both schizont-stage genes by 6 or 12
hours. Also, 500 nM DB75 drastically reduced peak inten-
sity of these late-stage genes. Merozoite surface protein-1
expression was reduced from a 139-fold increase to 0.7
(Figure 6c). Merozoite surface protein-7 peak expression
intensity was reduced from a 6.8 fold increase to 1.1.
Again, this is consistent with the delayed maturation effect
observed above.
Taken together, DB75 does not appear to enhance or sup-
press selected genes whose expression is associated with
specific lifecycle stages. However, delays in peak expres-
sion for mid- and late-stage expressed genes were
observed, and are consistent with the delays observed by
microscopy.
DB75 is representative of a class of newly synthesized dia-
midine compounds with anti-malarial activity. Confocal
microscopy demonstrates that DB75 co-localizes with a
nuclear DNA dye in the nucleus after both short (≤ 4
hours) and long exposures (24–72 hours) but not with
markers for other organelles, suggesting that DB75 may
target the nucleus. The absence of co-localized staining
with dyes for the mitochondrion or food vacuole argues
against these organelles as targets for DB75; however, due
to the complicated nature of fluorescence in the cell, these
organelles cannot be completely excluded.
By microscopy, DB75-treated cultures tended to stall in
the trophozoite stage. By quantifying transcription of six
stage specific genes, it is evident that DB75 causes delays
in expression but not inhibition of stage-specific tran-
scripts. Thus, both morphological and molecular evidence
suggests that DB75 may stall parasite maturation.
Previous reports suggest that the nucleus may be a target
for DB75. Epifluorescence and confocal microscopy stud-
ies show DB75 localizes to the nucleus and mitochondria
of tumor cells [14,26]. Additional studies show DB75
binds to the minor groove of DNA at 5'-AATT-3' [27].
Since the nuclear genome of P. falciparum is 80% AT rich,
the parasite genome may contain a high number of these
sites [28]. Thus, DB75 selectively accumulates in the
nucleus of both mammalian cells and P. falciparum.
The data suggest that DB75 has a different mechanism of
action in malaria than in trypanosomes. In trypanosomes,
epifluorescence experiments show that DB75 accumulates
in the mitochondria, acidocalcisomes, nucleus, and kine-
toplast [15,29]. Based on these observations, the accumu-
lation of DB75 in the nucleus, mitochondrion and/or
acidocalcisomes of Plasmodium was anticipated. How-
ever, the results suggest that subcellular localization of
DB75 is limited to the nucleus of the P. falciparum para-
site. While other subcellular sites cannot be eliminated
from consideration based solely on DB75 fluorescence,
the data presented are consistent with the observation that
DB75 does not affect malarial mitochondria (Akhil Vai-
dya, personal communication). Further molecular studies
may eliminate non-nuclear targets.
The results are not consistent with the mechanism of
action for diamidines proposed by Stead et al., who sug-
gest that diamidine compounds act by targeting the
haemozoin synthesis pathway in the food vacuole [12]. In
solution, 3 μM pentamidine binds haeme and prevents
haemozoin formation as determined by spectroscopy.
With confocal microscopy, DB75 does not accumulate in
the food vacuole with short term or long-term drug expo-
sure. One possible explanation for this lack of appearance
of drug in the food vacuole is fluorescent quenching at
low pH. However, DB75 fluorescence is not quenched by
low pH (J. Ed Hall, personal communication). Further
studies using electron micrographs or isotope-labelled
DB75 are needed to definitively rule out the food vacuole
as a target.
The effects of DB75 on parasite maturation might, in part,
be mediated by inhibition of genes transcribed early in the
life cycle when DB75 exposure appears to be critical. A
similar stage-specific inhibition was observed with the
anti-malarial compound, hexadecyltrimethylammonium
bromide, which inhibits late-stage expression of Plasmo-
dium falciparum choline kinase (pfck) [30].
Since only six stage-specific genes were tested, it is possi-
ble that DB75 may exert some specific effect on genes not
tested. A full microarray analysis may identify such specif-
icity if it exists in P. falciparum.
The increased DNA primase expression was unexpected.
DNA primase is required for DNA synthesis [31] and fur-
ther studies are needed to determine whether this is a gen-
eral response to cell death or is related to the drug
mechanism of action. DNA primase translational regula-
tion should also be investigated since DB75 binds to sin-
gle stranded RNA and could affect post-transcriptional
modification or translation [32].
While these data suggests that ring-infected parasites may
be more sensitive to DB75 than trophozoites, a recent
study by Hofer et al [33] suggests that trophozoites may be
more sensitive. However, this study used lower concentra-
tions and longer exposures than the Hofer et al study, so a
direct comparison cannot be made.Page 7 of 9
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parasites is imperfect. Parasites are synchronized at the
ring stage and examination of morphology shows > 90%
of the parasite population is at the desired state at the start
of experiments. The remaining unsynchronized parasites
may slightly skew gene expression and morphology
results. Second, classification by morphology of parasite
life stage is only approximate and imperfect. To minimize
this, the samples were blinded to prevent bias and all
morphology assessments were determined by one indi-
vidual. Third, the results presented here show that DB75
localizes in the nucleus, but the authors cannot defini-
tively say that this is the single target in P. falciparum.
DB75 may exhibit unknown fluorescent properties, such
as quenching, in the presence of biological substrates.
Therefore, it cannot be concluded that the compound is
not present when the fluorescence may, in fact, be
quenched. Finally, the complicated nature of capturing
images of live parasite-infected erythrocytes with confocal
microscopy limited the number of cells we were able to
examine.
Conclusion
Taken together, the results presented here suggest that
DB75 may target the nucleus and nucleic acid synthesis.
DB75 localizes in the nucleus and slows the maturation of
parasites. This is evident by the stall in development at the
trophozoite stage. In addition, DB75 must be present in
the early life stages to interrupt nuclear activity in the cell.
Inhibition of developmental gene transcription is not
likely to be the mechanism of action because alterations
with gene expression profiles occur only with the highest
concentration of DB75 and appear to be a result of the
stall in maturation. However, this study only examined
DB75's effect on the transcription of six select genes;
future studies should investigate the full extent of the
drug's effect on developmental gene expression using
microarrays. In addition, the effect of DB75 on DNA syn-
thesis, nuclear enzyme activity and mRNA translation
should be examined to further elucidate the mechanism
of action. This is the first time the mechanism for anti-
malarial action of DB75 has been evaluated. Results
obtained in this study are potentially relevant to the clin-
ical application of DB289. Also, these results may trans-
late to other dicationic diamidine compounds in
development for anti-malarial use.
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